β Home
βΉοΈ Info
π§Ύ Overview π Core Facts π₯ Video Blog β Ratings π§βπΌ Executives π¬ My Commentsπ‘ Analytics
π’ Company Q&A π οΈ Industry Q&A π Competitors π Stock Swings β‘ SWOT ποΈ PEST π Porter's Five Forces β¨ Score Positive β οΈ Risks π§© Segmentationπ§ Tools
β Due DiligenceFinancial Ratios
Pay attention and research significant changes from year to year values. [ ! ]
Fixed Column | Current Ratio | Quick Ratio | Cash Ratio | Days Of Sales Outstanding | Days Of Inventory Outstanding | Operating Cycle | Days Of Payables Outstanding | Cash Conversion Cycle | Gross Profit Margin | Operating Profit Margin | Pretax Profit Margin | Net Profit Margin | Effective Tax Rate | Return On Assets | Return On Equity | Return On Capital Employed | Net Income Per EBT | EBT Per EBIT | EBIT Per Revenue | Debt Ratio | Debt/Equity Ratio | Long Term Debt To Capitalization | Total Debt To Capitalization | Interest Coverage | Cash Flow To Debt Ratio | Company Equity Multiplier | Receivables Turnover | Payables Turnover | Inventory Turnover | Fixed Asset Turnover | Asset Turnover | Operating Cash Flow Per Share | Free Cash Flow Per Share | Cash Per Share | Payout Ratio | Operating Cash Flow / Sales Ratio | Free Cash Flow / Operating Cash Flow Ratio | Cash Flow Coverage Ratio | Short Term Coverage Ratios | Capital Expenditure Coverage Ratio | Dividend Paid And CAPEX Coverage Ratio | Dividend Payout Ratio | Price Book Value Ratio | Price To Book Ratio | Price To Sales Ratio | Price Earnings Ratio | Price To Free Cash Flows Ratio | Price To Operating Cash Flows Ratio | Price Cash Flow Ratio | Price Earnings To Growth Ratio | Price Sales Ratio | Dividend Yield | Enterprise Value Multiple | Price Fair Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-09 | 1.19 | 0.68 | 0.13 | 0 | 232.27 | 232.27 | 53.41 | 178.86 | 0.39 | 0.08 | 0.18 | 0.13 | 0.26 | 0.07 | 0.13 | 0.07 | 0.74 | 2.13 | 0.08 | 0.33 | 0.64 | 0.03 | 0.39 | 19.8 | 0.14 | 1.98 | 0 | 6.83 | 1.57 | 2.21 | 0.51 | 170.77 | -9.09 | 188.63 | 0.16 | 0.09 | -0.05 | 0.14 | 0.19 | 0.95 | 0.78 | 0.16 | 0.68 | 0.68 | 0.67 | 5.03 | -140.01 | 7.45 | 7.45 | 0.06 | 0.67 | 0.03 | 4.58 | 0.68 |
2023-09 | 1.31 | 0.66 | 0.08 | 145.54 | 290.08 | 435.62 | 84.94 | 350.68 | 0.4 | 0.09 | 0.11 | 0.08 | 0.22 | 0.04 | 0.08 | 0.07 | 0.78 | 1.14 | 0.09 | 0.34 | 0.7 | 0.17 | 0.41 | 31.88 | 0.07 | 2.07 | 2.51 | 4.3 | 1.26 | 1.99 | 0.48 | 78.88 | -81.48 | 531.16 | 0.26 | 0.05 | -1.03 | 0.07 | 0.12 | 0.49 | 0.4 | 0.26 | 0.69 | 0.69 | 0.69 | 8.25 | -14.31 | 14.78 | 14.78 | 0.3 | 0.69 | 0.03 | 7.29 | 0.69 |
2022-09 | 1.45 | 0.79 | 0.15 | 129.07 | 276.77 | 405.84 | 109.31 | 296.53 | 0.41 | 0.11 | 0.11 | 0.08 | 0.28 | 0.04 | 0.08 | 0.07 | 0.72 | 0.99 | 0.11 | 0.33 | 0.69 | 0.24 | 0.41 | 49.05 | -0.03 | 2.11 | 2.83 | 3.34 | 1.32 | 1.89 | 0.47 | -27.09 | -538.46 | 145.97 | 0.27 | -0.02 | 19.88 | -0.03 | -0.06 | -0.05 | -0.05 | 0.27 | 0.7 | 0.7 | 0.71 | 9.32 | -1.92 | -38.17 | -38.17 | 0.41 | 0.71 | 0.03 | 7.07 | 0.7 |
2021-09 | 1.73 | 1.13 | 0.51 | 127.42 | 227.78 | 355.2 | 108.39 | 246.81 | 0.43 | 0.1 | 0.1 | 0.07 | 0.28 | 0.04 | 0.07 | 0.08 | 0.72 | 1.01 | 0.1 | 0.29 | 0.57 | 0.17 | 0.36 | 63.19 | 0.32 | 1.97 | 2.86 | 3.37 | 1.6 | 2.36 | 0.53 | 223.06 | 78.05 | 278.93 | 0.33 | 0.18 | 0.35 | 0.32 | 0.68 | 1.54 | 1.27 | 0.33 | 0.96 | 0.96 | 0.92 | 12.93 | 14.99 | 5.25 | 5.25 | 0.37 | 0.92 | 0.03 | 7.31 | 0.96 |
2020-09 | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** |
2019-09 | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** |
2018-09 | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** |
2017-09 | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** |
2016-09 | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** |
2015-09 | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** |
2014-09 | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** | **** |

π Explore more ratios for Fuji Pharma!
Sign up for free or log in
Have you heard about our short Daily Video Newsletter?
Find out more